ResearchCRMabout 2 months ago11.6Kviews

Re-rating path for CRM

Healthcare: CRM over 21 days — demo research by @fatima_alhariri.

Fatima Al-Hariri on CRM. PhD pharmacology. I focus on PDUFA dates, trial readouts, and mispriced optionality in mid-cap biotech. Thesis: long over 21 days. Entry locked at publication. Risk: macro shock overwhelms the single-name view. [Demo seed content — not investment advice.]

Re-rating path for CRM

Discussion (0)